Applied DNA Sciences, Inc. - SIC # 8070 -

Ticker Exchange SIC # Website Latest Ticker
APDN Nasdaq 8070 www.adnas.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Applied DNA Sciences, Inc.

Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA - Apr 21st, 2025 1:00 pm
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement - Apr 8th, 2025 1:00 pm
Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement - Apr 1st, 2025 1:45 pm
Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test - Mar 26th, 2025 1:00 pm
Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025 - Mar 12th, 2025 12:00 pm
Applied DNA Sciences Inc (APDN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ... - Feb 14th, 2025 7:20 am
Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue Estimates - Feb 13th, 2025 10:20 pm
Applied DNA Sciences: Fiscal Q1 Earnings Snapshot - Feb 13th, 2025 9:18 pm
Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025 - Feb 12th, 2025 5:00 pm
Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14 - Feb 11th, 2025 1:30 pm
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates - Jan 10th, 2025 2:00 pm
Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter - Jan 8th, 2025 9:30 pm
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA - Dec 18th, 2024 2:00 pm
Applied DNA Sciences (APDN) Reports Q4 Loss, Tops Revenue Estimates - Dec 17th, 2024 10:15 pm
Applied DNA Sciences: Fiscal Q4 Earnings Snapshot - Dec 17th, 2024 9:12 pm
Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines - Dec 17th, 2024 9:05 pm
Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out - Dec 16th, 2024 3:00 pm
Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement - Oct 30th, 2024 11:15 am
Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16 - Oct 15th, 2024 2:30 pm
Applied DNA Sciences Inc (APDN) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines ... - Oct 9th, 2024 9:55 pm